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Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the
natural history of this prevalent and devastating condition. This review provides a concise, state of
the art summary on prevention and management of exacerbations. Considerable new data
underpins evidence in support of many preventative interventions, pharmacological and non-
pharmacological, that are now available. Challenges remain in developing new approaches, and
delivering those that already exist to the right patient at the right time. Management of an
exacerbation remains stepwise according to clinical severity, but there is now additional focus on
addressing comorbidities and taking the opportunity at acute events to optimise preventative
strategies for the future. Ultimately, exacerbations are heterogeneous events in a heterogeneous
disease, and an individualised approach is paramount.
Background
Affecting 10% of the population over the age of 40 years
[1], the burden of chronic obstructive pulmonary disease
(COPD) has reached epidemic proportions. COPD is
defined by the presence of poorly reversible airflow
obstruction and an abnormal inflammatory response in
the lung to noxious particles or gases [2]. Punctuating the
decline in lung function are acute deteriorations in respi-
ratory health, termed exacerbations. As discussed further
below, exacerbations are important events in the natural
history of COPD. This review provides a critical summary
of present exacerbation therapies and aims to update the
reader on recent developments in the treatment and pre-
vention of exacerbations in COPD.
The biology and importance of COPD 
exacerbations
Exacerbations are key events in COPD, defined by the
presence of worsening symptoms but also often associ-
ated with concurrent deteriorations in pulmonary func-
tion and increases in both local and systemic
inflammation [3]. Exacerbations are caused by those
insults that increase airway inflammation, principally epi-
sodes of bronchial infection, but also pollutants or stimuli
that directly affect expiratory flow limitation [3].
Although it is generally true that exacerbations become
more frequent as the severity of the underlying COPD
increases [4], there are large differences in exacerbation
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incidence rates ('exacerbation frequency') between indi-
vidual patients, and patients susceptible to more frequent
exacerbations ('frequent exacerbators') appear to be a dis-
tinct phenotype susceptible to a more rapid decline in
lung function [5,6], poorer quality of life [7] and
increased mortality [8]. They are therefore a particularly
important group to target for the exacerbation prevention
strategies that are described below. There is emerging evi-
dence to suggest that a proportion of patients with milder
COPD may be susceptible to frequent exacerbations [9].
Exacerbations are very heterogeneous events ranging from
no more than troublesome increases in respiratory symp-
toms to life-threatening episodes of respiratory failure. A
typical community-treated exacerbation in a patient with
moderately severe COPD has a short prodrome and a
median symptom duration of 7 days, though some are
considerably longer and a proportion of patients may
never completely return to their pre-exacerbation baseline
[10]. Exacerbations in more severe disease commonly
require hospitalisation, and they are a much more com-
mon cause of emergency hospital admission than, for
example, exacerbations of asthma [4]. Therefore, in addi-
tion to significant personal detriment to the patient, exac-
erbations of COPD demand a considerable portion of
healthcare expenditure. Moreover, with an ageing popula-
tion and relatively greater reductions in mortality from
other prevalent diseases (notably cardiovascular disease)
the burden of exacerbations continues to rise [1].
Exacerbation diagnosis and treatment
Exacerbations of COPD remain a clinical diagnosis of
exclusion, and it is necessary to consider (and, where
appropriate, rule out) other causes of increased breath-
lessness in patients with COPD presenting with symptom
deteriorations [11]. Conditions mimicking exacerbations
include pneumonia, pneumothorax, pulmonary embolus
and cardiac failure. Diagnosis of exacerbation therefore
requires appropriate clinical assessment and may need
further investigation with, for example, chest radiography.
The principles of exacerbation therapy have not changed
greatly since the widespread introduction in the 1990s of
non-invasive ventilation in preference to doxapram for
the treatment of hypercapnoea at exacerbation of COPD.
Therapies at exacerbation may be divided into those
thought to have a disease-modifying effect, and those
aiming to support respiratory function until disease-mod-
ifying therapies have had sufficient time to act.
Exacerbation therapy is administered stepwise according
to the clinical severity of presentation, and a general
scheme is presented in Figure 1. It is important to note
that disentangling the concept of exacerbation severity
from the severity of the underlying COPD is almost
impossible: a patient needing intubation and ventilation
at exacerbation may have milder disease with a greater
acute deterioration, or more severe underlying disease and
a trivial insult.
The mainstay of therapy at exacerbation remains an
increase in the dose and frequency of short-acting β2 ago-
nist and anticholinergic bronchodilators, and systemic
corticosteroids for exacerbations not responding to this
intervention alone. Antibiotics are generally added for
exacerbations associated with a change in the characteris-
tics of expectorated sputum. Oxygen with or without ven-
tilatory support is necessary in the presence of respiratory
failure, and often indicates the need for hospitalisation.
Theophyllines are sometimes added in patients respond-
ing poorly to other therapies. Many national and interna-
tional guidelines exist [12,13].
Reviewing data from the original trials of these commonly
prescribed therapies challenges our rationale for their use.
Many exacerbations in the seminal study of antibiotics
versus placebo improved in the placebo arm anyway [14],
and the value of antibiotics has recently been further ques-
tioned in a systematic review in this journal [15]. There
certainly appears to be no additional benefit from antibi-
otic courses lasting longer than 5 days compared to
shorter regimes [16]. The major benefit of systemic corti-
costeroids is in increasing the rate of recovery of lung
function, rather than more important endpoints such as
mortality [17]. Indeed, there is evidence of relative corti-
costeroid resistance in COPD [18]. Whilst acknowledging
the methodological limitations of such approaches, meta-
analyses are available reporting summarised benefits at
exacerbation for short-acting bronchodilators [19], sys-
temic corticosteroids [20], antibiotics [21], theophyllines
[22] and non-invasive ventilation (NIV) [23]. NIV has
now all but replaced respiratory stimulants such as doxa-
pram in the management of exacerbations with acute
hypercapnoeic respiratory failure, and meta-analyses of
NIV have documented a mortality benefit from such ther-
apy over standard care [23]. However, NIV is not a
replacement for endotracheal intubation and ventilation
where this is necessary through severity or contraindica-
tion to NIV. Whilst the decision to intubate and ventilate
a patient with COPD can be complex, outcomes in COPD
are no worse than in patients with respiratory failure due
to other causes [24] and any remaining therapeutic nihil-
ism in this area should be challenged.
There is continuing interest in novel models of care
including 'hospital at home'. Most data suggest that for
selected patients such schemes are safe, and often pre-
ferred by patients [25], but that they are not necessarily
more cost effective than traditional approaches.
Whilst pulmonary rehabilitation has an important role in
preventing hospitalisations in COPD (discussed below),BMC Medicine 2009, 7:40 http://www.biomedcentral.com/1741-7015/7/40
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the concept of 'early rehabilitation' commenced during an
acute exacerbation has not been definitively associated
with improved outcomes. These results from a recent ran-
domised controlled trial [26] contrast with those from an
earlier meta-analysis of six smaller studies [27].
Intriguingly, further new data has suggested that treat-
ment provided at a first exacerbation may affect the timing
of second events. The addition of antibiotics to steroids,
for example, has been associated with a reduced risk of
subsequent recurrent exacerbation [28]. Indeed, it is now
recognised that exacerbations are not random events, but
rather cluster together in time such that in the period
immediately following a first exacerbation there is
increased risk of a second [29].
Future developments might be expected to include the
validation of biomarkers to provide information on exac-
erbation aetiology and novel drugs, particularly antiviral
agents and alternative anti-inflammatory agents to corti-
costeroids. Use of procalcitonin to inform on the likeli-
hood of bacterial aetiology has been shown to safely
reduce the use of antibiotics at exacerbation [30], but this
concept is now complicated by the data referred to above
suggesting that antibiotic treatment at one exacerbation
may affect the timing of subsequent events [28]. It is also
important to remark that the presence of bacteria in spu-
tum at exacerbation does not imply that the organism is
causative, and sputum bacterial colonisation is a frequent
consequence of advancing COPD severity [31].
A final aspect of exacerbation therapy is data demonstrat-
ing that access to early treatment speeds exacerbation
recovery [32] and this has led to many patients receiving
'emergency' courses of treatment to keep at home. How-
ever, data to specifically support self-management strate-
gies (which requires self-diagnosis) are absent [33,34].
Exacerbation prevention
In contrast to treatment of acute events, recent years have
seen publication of landmark trials in COPD which
inform on exacerbation prevention and we now have a
wide range of options available, both pharmacological
and non-pharmacological, to reduce exacerbation fre-
quency. These are listed in Table 1, which also includes
interventions known to reduce COPD hospitalisation (a
closely related concept). Perhaps the greatest remaining
challenge is to establish which patient will benefit from
which combination of approaches, though there is still
the need for novel interventions as current approaches are
incompletely effective.
Recent trials
Although it has been known for some time that the three
main classes of inhaled medication in COPD (corticoster-
oids, and long-acting anticholinergic and β2 agonist bron-
chodilatiors) all reduce exacerbation frequency, there is
compelling new data with regard to these drugs.
The TORCH trial (for 'TOwards a Revolution in COPD
Health') [35] was published in 2007 and compared pla-
cebo, salmeterol, fluticasone and salmeterol-fluticasone
(SFC) against a primary end point of all cause mortality.
A total of 6,112 patients formed the efficacy population
and the study duration was 3 years. Mortality data was
carefully collected. The study supports the concept that
combination treatment with SFC may reduce mortality,
Table 1: Interventions known to reduce exacerbation frequency 
or frequency of hospitalisation in chronic obstructive pulmonary 
disease (COPD)
Pharmacological Non-pharmacological
Long-acting β2 agonists Pulmonary rehabilitation
Long-acting anticholinergics Lung volume reduction surgery
Inhaled corticosteroids Long-term oxygen therapy
Mucolytics Domiciliary non-invasive ventilation
Erythromycin (macrolide) Influenza vaccination
General scheme for management of a chronic obstructive  pulmonary disease (COPD) exacerbation Figure 1
General scheme for management of a chronic 
obstructive pulmonary disease (COPD) exacerba-
tion. Therapy is added stepwise according to the severity of 
the presentation. Mild exacerbations may respond to an 
increase in the dose and/or frequency of inhaled bronchodila-
tors alone. Exacerbations not responding to this require sys-
temic corticosteroids, with the addition of antibiotics if there 
has been a change in the character of expectorated sputum. 
Additional interventions such as theophylline may be 
required where the clinical response is still incomplete. Oxy-
gen and/or ventilatory support may be necessary at any stage 
in the presence of new or established respiratory failure. 
Exacerbation management should also include an assessment 
and management of comorbidities, and the opportunity 
should be taken to optimise long-term therapies to reduce 
the risk of future exacerbations.BMC Medicine 2009, 7:40 http://www.biomedcentral.com/1741-7015/7/40
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but at P = 0.052 this just failed to achieve conventional
statistical significance. Secondary outcomes included
exacerbations and, supporting multiple earlier studies,
there was evidence that all three active arms reduced exac-
erbations compared to placebo, with combination (SFC)
treatment significantly better than either component
alone. The annual rate of moderate and severe exacerba-
tions in the placebo group was 1.13 per year, compared to
0.97 for salmeterol, 0.93 for fluticasone and 0.85 in
patients receiving SFC. Like the subsequent trials
described below, there was a significant preferential drop
out rate from the placebo arm, complicating analysis, but
which also represents a useful efficacy signal.
The Understanding Potential Long-term Impacts on Func-
tion with Tiotropium (UPLIFT) trial [36] was published in
2008 and compared the addition of tiotropium or pla-
cebo to current therapies with a primary end point of lung
function decline. A total of 5,993 patients were ran-
domised and the study duration was 4 years. The primary
end point was negative, and once again the secondary
endpoints included exacerbations. The addition of tiotro-
pium resulted in a significant reduction in exacerbation
frequency (0.73 per year tiotropium vs. 0.85 per year pla-
cebo, P < 0.001), which is important given that many
patients were already taking combined inhaled corticos-
teroids with long-acting β2 agonists.
The latter 'triple combination' approach is common in
advanced COPD, and the only study to specifically exam-
ine this to date has been the Canadian OPTIMAL study
[37]. This randomised 449 patients on tiotropium to
additional placebo, salmeterol or SFC and had a 1-year
duration. There was not a reduction in the primary end-
point of exacerbations in patients on tiotropium plus
other therapy compared to tiotropium alone. These
results are in keeping with a recent network meta-analysis
published in this journal [38]. However, hospitalisations
due to severe exacerbations were reduced in the group
receiving tiotropium and SFC compared to tiotropium
alone. Once again, patients on placebo were more likely
to drop out. These data therefore question the 'triple com-
bination' approach, at least with respect to the prevention
of exacerbations and raise the concerning possibility of a
ceiling effect for exacerbation preventative strategies.
The only head-to-head comparison of tiotropium versus
SFC has been the Investigating New Standards for Proph-
ylaxis In Reduction of Exacerbations (INSPIRE) study
[39]. This randomised 1,323 patients to salmeterol-fluti-
casone or tiotropium over 2 years. Both treatments, as
expected, reduced exacerbation frequency, and to a simi-
lar degree (to 1.28 per year for SFC and 1.32 per year for
tiotropium, with a ratio of rates of 0.97 (95% CI 0.84 to
1.12)). Intriguingly however, the remaining exacerbations
appeared to differ in phenotype depending on which drug
the patient was taking: patients on SFC were more likely
to need antibiotics at exacerbation whilst patients on tio-
tropium were more likely to require steroids. Which
patients benefit most from which drug remains to be clar-
ified. Perhaps a more important decision, which also
remains to be adequately addressed, is which strategy to
employ first in patients with milder disease.
Other strategies
Inhaled corticosteroids in combination with long-acting
β2 agonists, and long-acting anticholinergics are the prin-
cipal pharmacological approaches to exacerbation reduc-
tion in COPD at present. Whilst combination
corticosteroid and long-acting β2 agonist therapy is rec-
ommended in both asthma and COPD, it is interesting to
note that it is the inhaled corticosteroid that has had safety
concerns in COPD, compared to the long-acting β2 ago-
nist component in asthma [40]. There is also evidence
that mucolytics such as carbocisteine may be effective,
especially in patients not taking inhaled corticosteroids
[41]. Macrolide antibiotics have additional anti-inflam-
matory action and a recent single-centre, double-blind
randomised trial of erythromycin 250 mg twice a day over
1 year reported a 35% reduction in exacerbations [42].
Further confirmatory trials are ongoing. Other trials of
prophylactic antibiotics are generally older [43], and there
are ongoing concerns about the development of antibiotic
resistance. Nevertheless, new strategies for the use of anti-
biotics are being studied such as intermittent or 'pulsed'
therapy. As exacerbations are associated with additional
inflammation, the effect of corticosteroids and macrolides
in reducing exacerbations is perhaps to be expected. How-
ever, this would not explain the beneficial effect of 'pure
bronchodilator' drugs such as tiotropium. It seems likely
that a reduction in hyperinflation can also reduce exacer-
bation frequency (though tiotropium also has effects on
mucus rheology).
New developments include ultra-long-acting (once daily)
β2  agonists and corticosteroids, and bronchodilators
which possess both antimuscarinic and β2 agonist activity.
New classes of drugs are in development too, though
none have yet been demonstrated to have an effect on
exacerbation frequency.
Depression and anxiety are common in COPD [44], and
likely also affect symptom perception and therefore exac-
erbation presentation. It is therefore important to detect
and treat comorbid psychological conditions in COPD,
though a specific effect on exacerbation reduction has not
been documented.
Non-pharmacological approaches include influenza vac-
cination [45] and the recognised benefit in reducing hos-BMC Medicine 2009, 7:40 http://www.biomedcentral.com/1741-7015/7/40
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pitalisation of group, multiprofessional exercise and
educational programmes (pulmonary rehabilitation)
[46]. These programmes appear greater than the sum of
their parts, and benefit from peer support. The finding
that lung volume reduction surgery (LVRS; an approach in
severe disease with heterogeneous distribution) reduced
exacerbation frequency was perhaps unexpected [47] and
this may also reflect the benefits of reducing hyperinfla-
tion. Criteria for long-term oxygen therapy (LTOT) are
well established, and LTOT is one of the few interventions
proven to have a mortality benefit in COPD [48,49].
Whilst a specific effect of oxygen on reducing exacerba-
tions has not been demonstrated, there is evidence that
underuse of LTOT where indicated results in increased
hospital admissions [50]. A recent study has suggested
that domiciliary NIV for COPD patients with hypercap-
noeic respiratory failure may improve survival [51], but
robust data in this field with regard to exacerbations also
remain to be produced.
Conclusion
Exacerbations are important events in COPD. Manage-
ment of the acute event remains dependent on inhaled
short-acting bronchodilators, oral corticosteroids and
antibiotics, with or without oxygen and ventilatory sup-
port. Comorbidities should be addressed. Given the
importance of these events, effective care should also
include deployment of strategies, both pharmacological
and non-pharmacological, to reduce future exacerbations.
Although new approaches are in development, a major
current challenge is to understand which strategies to use
in which patients at which stage of their disease. COPD
exacerbations are heterogeneous events occurring in a het-
erogeneous disease and there is no 'one size fits all'
approach to COPD exacerbation management and pre-
vention.
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